Hims & Hers Health heads into its August 3 earnings report with short interest re-entrenched, options positioning nudging more cautious, and a stock that just bounced 8% on Thursday after losing 17% over the prior week.
The short setup has changed direction since earlier this month. Short interest has now risen roughly 4% over the past week to 27.8% of the free float — about 61 million shares — reversing a weeks-long unwind that had seen positions gradually ease from the late-June peak near 64 million. That stalled retreat matters: the reflexive squeeze fuel that might have amplified a positive print is less available than it was a month ago. The ORTEX short score has held firmly in the high 60s at 69.97, consistent with recent sessions and well above what would be considered neutral territory. Availability has tightened slightly to 42%, down roughly 11% on the week — still loose enough relative to mid-June's near-zero readings, when borrowing was nearly impossible, but moving in the wrong direction for would-be shorts. Cost to borrow remains negligible at 0.88%, so there is no financial pressure forcing short sellers to cover.
Options traders have also tilted more guarded into the release. The put/call ratio has climbed to 0.63, roughly 1.7 standard deviations above its 20-day average of 0.59 — not an extreme reading, but the most defensive positioning has been in several months. That compares with a 52-week high of 1.52, so there is plenty of room for further defensiveness to build. The modest tilt toward puts fits a stock that has shed nearly 20% over the past month and where Thursday's 8% bounce may reflect short-covering ahead of Monday rather than a genuine change in sentiment.
The analyst community is largely on the sidelines, with the consensus sitting at hold. That said, target prices have been moving upward. Truist raised its target to $27 last week, Citigroup lifted to $35, and Bank of America moved to $37 — all while maintaining neutral or hold ratings. The current price of $27.04 essentially trades at Truist's floor, well below the Citigroup and BofA targets, which suggests the Street sees recovery potential but is not yet willing to recommend buying. The bull case rests on the Novo Nordisk collaboration and the company's subscriber retention strategy; bears point to the downward revision to FY26 adjusted EBITDA guidance and the structural costs of entering and scaling in the GLP-1 market. The EPS surprise factor score ranks in just the 4th percentile — the company has consistently disappointed on earnings — though the 30-day forward EPS momentum has turned sharply positive, which may reflect expectations for a cleaner print this time.
Past reactions add another layer of uncertainty. The May earnings release triggered an 11.5% one-day drop followed by a 21% five-day decline. The June report saw a smaller immediate fall of 3.5% but then recovered 28% over five days. Monday's print will therefore test whether the company can offer enough clarity on its profitability path — particularly around the GLP-1 infrastructure spend and any update on the Novo Nordisk partnership — to break the pattern of disappointing the market on the bottom line even when the top line holds.
See the live data behind this article on ORTEX.
Open HIMS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
